Given the limitations of sample sizes and individual variability, these findings warrant careful interpretation [8]
Additionally, novel combination therapiessuch as Tirzepatide, which combines a GLP-1 analogue with glucose-dependent insulinotropic polypeptide (GIP)-are rapidly gaining traction, and it is expected that new formulations will continue to emerge, incorporating peptides capable of modulating metabolism and thermogenesis (Jastreboff et al., 2022
The UK does operate regulated frameworks for pre-authorisation access to medicines including the Early Access to Medicines Scheme (EAMS) and named-patient unlicensed supply however, neither of these routes is currently applicable to retatrutide
The numbers tell a compelling story, and its one that cannot be ignored
doi:10.1093/ajcn/77.1.133 Gianetti J, Pedrinelli R, Petrucci R, et al